{
    "clinical_study": {
        "@rank": "102590", 
        "acronym": "Disease", 
        "arm_group": [
            {
                "arm_group_label": "Protopic Arm", 
                "arm_group_type": "Experimental", 
                "description": "Protopic\u00ae 0.1% ointment - 2 applications per week for 6 months"
            }, 
            {
                "arm_group_label": "Mycoster Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "2 applications per week for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by\n      relapses, affecting mainly the face and scalp. It would be important to have a maintenance\n      treatment for severe forms of seborrheic dermatitis witch is both effective and relatively\n      well tolerated to reduce the frequency of relapses, prolong remissions obtained after attack\n      treatment and reduce the use of topical steroids."
        }, 
        "brief_title": "Tacrolimus Ointment Interest (PROTOPIC \u00ae) in the Maintenance Treatment of Severe Seborrheic Dermatitis", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Seborrheic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Seborrheic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  in Phase 1: Attack Treatment (open)\n\n               1. over the age of eighteen patient,\n\n               2. Seborrheic dermatitis Severe,\n\n               3. participation with an informed consent,\n\n               4. Women of childbearing age in effective contraception for the duration of the\n                  study or postmenopausal women.\n\n          -  in Phase 2: Phase 2: \"Randomization\" (blind)\n\n               1. Patient achieved a complete or almost complete clinical remission after the\n                  initial treatment,\n\n               2. known immunodeficiency (HIV patient receiving chemotherapy) or immunosuppressive\n                  therapy or biotherapy,\n\n               3. patient taking regular systemic corticosteroids at a dose> 20 mg / day\n\n               4. erythematous lesions with topography other than the face and evocative scalp\n                  psoriasis (elbows, knees ...), by referring to the possibility that the facial\n                  lesions correspond to lesions sebopsoriasis,\n\n               5. woman pregnant, nursing or in childbearing potential without effective\n                  contraception,\n\n               6. man wishing to have a child during the study period,\n\n               7. Ultra Violet (UV) phototherapy or usual realization of UV sessions aesthetic\n                  purposes,\n\n               8. Seborrheic dermatitis symptomatic of an underlying disease known or revealing\n\n               9. history of cancer or lymphoma,\n\n              10. progressive cancer or lymphoma,\n\n              11. Seborrheic dermatitis exclusively affecting the scalp,\n\n              12. known allergy to one-component products study ,\n\n              13. malnourished patient or sick history of chronic pancreatitis by a suspect to\n                  deficiency dermatitis,\n\n              14. participation in a clinical trial on the Seborrheic dermatitis in the previous\n                  90 days,\n\n              15. patient with lesions considered potentially malignant or pre-cancerous,\n\n              16. patient with abnormal skin barrier.\n\n        Exclusion Criteria:\n\n          -  in Phase 1: Attack Treatment (open)\n\n             1) Patient had already been treated with Protopic \u00ae for Seborrheic Dermatitis,\n\n          -  Phase 2: \"Randomization\" (blind) 1) Patient with no complete or almost complete\n             clinical remission after the initial treatment,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004860", 
            "org_study_id": "2011/104/HP", 
            "secondary_id": "2011-004186-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "Protopic Arm", 
                "description": "Protopic\u00ae 0.1% ointment - 2 applications per week for 6 months", 
                "intervention_name": "Protopic (R)", 
                "intervention_type": "Drug", 
                "other_name": "Tacrolimus"
            }, 
            {
                "arm_group_label": "Mycoster Arm", 
                "description": "Mycoster 1% - 2 applications per week for 6 months", 
                "intervention_name": "Mycoster (R)", 
                "intervention_type": "Drug", 
                "other_name": "Ciclopirox olamine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ciclopirox", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "local immunosuppressive", 
            "Maintenance therapy"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "pascal.joly@chu-rouen.fr", 
                "last_name": "Pascal Joly, Professor", 
                "phone": "2 32 88 68 41", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "philippe.musette@chu-rouen.fr", 
                "last_name": "philippe Musette, professor", 
                "phone": "2 32 88 68 41", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Rouen", 
                    "country": "France", 
                    "zip": "76031"
                }, 
                "name": "Rouen University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 : Tacrolimus Ointment Interest (PROTOPIC \u00ae) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face", 
        "overall_contact": {
            "email": "pascal.joly@chu-rouen.fr", 
            "last_name": "Pascal JOLY, Professor", 
            "phone": "2 32 88 68 41", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "philippe.musette@chu-rouen.fr", 
            "last_name": "Philippe MUSETTE, Professor", 
            "phone": "2 32 88 68 41", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Rouen", 
            "last_name": "Pascal JOLY, Professor", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint will be the duration of the maintenance of complete or almost complete clinical remission obtained after the initial treatment. This period is defined as the time from randomization to the first occurrence of relapse noted by the dermatologist.", 
            "measure": "duration of the maintenance of complete or almost complete clinical remission", 
            "safety_issue": "No", 
            "time_frame": "18 months after inclusion (Visit (V) 4 last visit)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tolerance of 2 treatments Mycoster (R) and Protocopic (R)", 
                "measure": "Tolerance of 2 treatments", 
                "safety_issue": "No", 
                "time_frame": "between 10 days and 18 months after inclusion (V3 (Day (D)10 to D180)), 30 days after inclusion (Visit D30), after 90 days after inclusion (D90) and after 120 days after inclusion (D120) and 180 days after inclusion (Visit V4)"
            }, 
            {
                "description": "Number of Relapses requiring the resumption of topical corticosteroid treatment,", 
                "measure": "Number of Relapses", 
                "safety_issue": "No", 
                "time_frame": "180 days after inclusion (Visit V4)"
            }, 
            {
                "description": "Cumulative amount of corticosteroids applied by the patients during the study period to control their outbreaks", 
                "measure": "Cumulative amount of corticosteroids applied", 
                "safety_issue": "No", 
                "time_frame": "between 10 days and 18 months after inclusion (V3 (D10 to D180)), 30 days after inclusion (Visit D30), after 90 days after inclusion (D90) and after 120 days after inclusion (D120) and 180 days after inclusion (Visit V4)"
            }, 
            {
                "description": "quality of life of patients", 
                "measure": "quality of life of patients", 
                "safety_issue": "No", 
                "time_frame": "Inclusion (visit D0) and Last visit 180 days after inclusion (Visit D180)"
            }
        ], 
        "source": "University Hospital, Rouen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Rouen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}